KYTX logo

KYTX Kyverna Therapeutics, Inc.

NASDAQ · Biotechnology · Healthcare

$4.26
-0.11 (-2.52%)

Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and lupus nephritis, as well as multiple sclerosis and systemic sclerosis. The company is also develop…

Market Cap: $269.33Mkyvernatx.com

Price

No data yet.

Social Signal Score

49
5d
—
30d
43
3 mentions
—
60d
51
6 mentions
—
90d
53
8 mentions
—
news: 8

Analyst Ratings

4 analysts
Buyconsensus
Strong Buy 0Buy 4Hold 0Sell 0Strong Sell 0
Avg price target$25+486.9%
Low $25Median $25High $25
Current Consensus

Revenue

$0.00-100.00%
$0.00$94.0K$188.0K$282.0K
Dec 2022Sep 2026

Analyst Estimates

FY2025
$-3.69
$-3.80–$-3.48
5 analysts
FY2026
$-2.69
$-2.74–$-2.65
5 analysts
FY2027
$-2.97
$-3.42–$-2.76
5 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Warner Biddle
Sector
Healthcare
Industry
Biotechnology
Employees
149
Beta
2.13
Country
US
Piotroski score
2 / 9 (Weak)
Altman Z-score
-2.90
kyvernatx.com